Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in phase 2 ...

Harnessing immunogenic cell death (ICD)—an immunostimulatory form of cancer cell death in the tumor microenvironment—to help activate a patient’s immunity and trigger a tumor-specific immune ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

THURSDAY, Feb. 6, 2025 (HealthDay News) -- Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell carcinoma (RCC) and can target key ...

Get Instant Summarized Text (Gist) A self-assembling nanoplatform has been developed to enhance cancer photoimmunotherapy by targeting tumor cells and inducing immunogenic cell death through ...

“These data demonstrate that our first-in-human vaccine based on our PlaCCine platform is safe and immunogenic and is well-suited to developing vaccine candidates for protecting the population ...

Imunon CEO and president Stacy Lindborg said: “These data demonstrate that our first-in-human vaccine based on our PlaCCine platform is safe and immunogenic and is well-suited to developing ...